Litcius/Paper detail

EGFR activation limits the response of liver cancer to lenvatinib

Haojie Jin, Yao Shi, Yuanyuan Lv, Shengxian Yuan, Christel Ramirez, Cor Lieftink, Liqin Wang, Siying Wang, Cun Wang, Matheus Henrique Dias, Fleur Jochems, Yuan Yang, Astrid Bosma, E. Marielle Hijmans, Marnix H. P. de Groot, Serena Vegna, Dan Cui, Yangyang Zhou, Ling Jing, Hui Wang, Yuchen Guo, Xingling Zheng, Nikita Isima, Hai-Qiu Wu, Chong Sun, Roderick L. Beijersbergen, Leila Akkari, Weiping Zhou, Bo Zhai, Wenxin Qin, René Bernards

2021Nature435 citationsDOI

Topics & Concepts

LenvatinibGefitinibKinomeMedicineErlotinibCancer researchEGFR inhibitorsEpidermal growth factor receptorLiver cancerPharmacologyCancerSorafenibTyrosine kinaseOncologyInternal medicineKinaseHepatocellular carcinomaBiologyReceptorCell biologyCancer Mechanisms and TherapyHepatocellular Carcinoma Treatment and PrognosisPI3K/AKT/mTOR signaling in cancer
EGFR activation limits the response of liver cancer to lenvatinib | Litcius